In his first appearance in a Vioxx trial, the former chief executive of Merck & Co. insisted Thursday that the company was up front about the safety risks of its troubled arthritis drug during his tenure — despite a jury verdict to the contrary.
In his first appearance in a Vioxx trial, the former chief executive of Merck & Co. insisted Thursday that the company was up front about the safety risks of its troubled arthritis drug during his tenure — despite a jury verdict to the contrary.
